Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)

Stopped A strategic decision was made to discontinue the study. The decision was not based on a safety concern.

Conditions

• Respiratory Syncytial Virus Infections

Interventions

• DRUG: JNJ-53718678 250 mg
• DRUG: Placebo
• DRUG: JNJ-53718678 125 mg

Sponsor

Janssen Sciences Ireland UC